Health Care

BD’s 1,330‑share Form 144 sale shows a routine insider exercise—yet it hints at executive sentiment, compensation structure, and governance trends in the diagnostics market.

Thermo Fisher’s insider trading, equity strategy and AI‑driven biobanking outlook reveal a blend of liquidity moves, shareholder confidence and growth risks that could shape its market position.

Novonesis boosts Q2 earnings, raises growth outlook, and partners with Novo Nordisk to combine microbiome supplements with GLP‑1 weight‑loss drugs for safer, stronger results.

Siemens Healthineers navigates reimbursement tightening while boosting German R&D, AI imaging and profit margins, positioning for steady growth and shareholder value.

Discover why Sartorius AG’s bioprocessing surge bucks German equity downturns, highlighting single‑use tech gains, regulatory strength, and investor upside.

Fresenius SE & Co. divests 7.8 M FMC shares, raising €300 M to trim debt and fuel growth in digital health, biopharma and ESG‑focused initiatives.

Explore Bayer’s groundbreaking phase‑III cardiovascular, kidney and stroke data revealed at ESC 2026, from finerenone outcomes to new amyloidosis imaging and asundexian stroke prevention.

Merck KGaA’s voting‑rights filing reveals how a pharma giant navigates reimbursement pressure, supply‑chain disruptions and shifting investor expectations while keeping EBITDA and margins above industry averages.

Pfizer’s 1H 2026 results show strong earnings driven by milestone income from the SSGJ‑707 partnership, alongside growing oncology and obesity revenues, positioning the company for sustained growth.

Johnson & Johnson’s strategy: diversified portfolio, value‑based contracts, and a pipeline boost to keep margins high amid patent cliffs.